QT Imaging Secures NIH Grant Renewal for Cancer Response Study
QT Imaging Holdings, Inc. (NASDAQ: QTI), a leading medical device company based in Novato, California, is thrilled to announce that it has received a renewal for the third year of its five-year research grant awarded by the National Institutes of Health (NIH) and the National Cancer Institute (NCI). This significant advancement in funding supports collaborative research aimed at harnessing innovative approaches in body imaging systems to improve breast cancer diagnostics.
Collaboration with Prestigious Institutions
This promising study is developed in partnership with the Department of Radiation Oncology and the Radiation Treatment Program at a prominent cancer center in Toronto, alongside The University of Illinois at Urbana-Champaign's Engineering Department. Together, these institutions form a strong backbone for research targeting early identification and effective response monitoring for patients undergoing neoadjuvant chemotherapy (NAC).
A Novel Imaging Approach
The primary objective of this pivotal project is to craft a reliable, quantitative, and portable imaging method that can accurately detect how breast cancer patients respond to neoadjuvant chemotherapy. By collecting quantitative breast images alongside independent biomarkers that are sensitive to cancer, researchers aim to analyze the nuances of cancer response comprehensively.
Advancements in Imaging Technology
To achieve this goal, QT Imaging has utilized the QTI Breast Acoustic CT™ System, which was set up earlier at Sunnybrook Health Sciences Centre. This advanced system captures high-resolution breast images, which are essential for analyzing patient responses effectively. The successful testing of the backscatter analysis technique on in vivo breast imaging data marks a critical step forward in this research.
Incorporating AI and Machine Learning
Building on recent progress, the research team intends to incorporate advanced algorithms into the QTI image reconstruction process. By utilizing artificial intelligence (AI) and machine learning (ML) techniques, they aim to enhance estimates of NAC efficacy based on these quantitative biomarkers, paving the way for new insights that were previously unattainable with standard imaging methods.
Expert Insights
Dr. James Wiskin, PhD and Principal Data Scientist at QT Imaging, expressed enthusiasm regarding the project's progress: "We are extremely encouraged by our study's preliminary results and are honored to collaborate with experts like Michael Oelze and Greg Czarnota. Renewing this grant strengthens our commitment to finding therapies that yield results in days rather than months for cancer patients."
QT Imaging Holdings, Inc. Overview
QT Imaging Holdings, Inc. is publicly traded under the ticker NASDAQ: QTI, focusing on the research, development, and commercial deployment of cutting-edge body imaging systems that utilize low-frequency sound waves. The organization is dedicated to enhancing health outcomes globally by ensuring medical imaging is safe, accessible, and cost-effective, always keeping the patient experience at the forefront.
Frequently Asked Questions
What is the focus of the renewed NIH study by QT Imaging?
The study centers on developing an innovative imaging approach to identify how breast cancer patients respond to neoadjuvant chemotherapy more effectively.
Which technology is being used in the study?
The QTI Breast Acoustic CT™ System is utilized to capture high-resolution breast images for the research.
What kind of collaboration supports this study?
QT Imaging collaborates with prestigious institutions, including a leading Canadian cancer center and The University of Illinois.
How does AI and machine learning play a role in this research?
AI and ML techniques will be integrated into the imaging process to provide more accurate estimations of therapy efficacy based on quantitative biomarkers.
What is QT Imaging's mission?
QT Imaging aims to improve global health outcomes by ensuring medical imaging is safe, affordable, and centered on the patient's experience.
